论文部分内容阅读
本文报告大剂量丁地去炎松(budesonide)气雾剂治疗类固醇依赖性重症哮喘患者的疗效。病人和方法 18例重症哮喘患者,平均年龄46.1岁,男7例。女11例。平均哮喘病程17.8年。所有患者依赖类固醇至少2年,每天需口服泼尼松龙7.5mg 以控制症状,且均出现了类固醇副作用。开始应用丁地去炎松气雾剂1mg 每天2次,然后增至2mg 每天2次(部分患者增至4mg 每天2次),总疗程12～18个月以上;同时继续应用其它抗哮喘药。于研究前及结束时测定第1秒用力呼气量(FEV_1)、呼气流速峰值(PEFR)等;记录患者哮喘症状、口服泼尼松龙用量以及每年因哮喘发作住院的次数。
This article reports the efficacy of high-dose budesonide aerosol in patients with steroid-dependent severe asthma. Patients and Methods 18 cases of severe asthma patients, mean age 46.1 years, 7 males. Female 11 cases. The average duration of asthma 17.8 years. All patients were dependent on steroids for at least 2 years and were given oral prednisolone 7.5 mg daily to control their symptoms and all had steroid side effects. Begin to apply Ding to the inflammatory relaxant aerosol 1mg 2 times a day, then increased to 2mg 2 times a day (some patients increased to 4mg twice daily), the total course of 12 to 18 months or more; continue to use other anti-asthma drugs. The forced expiratory volume at 1 second (FEV 1) and peak expiratory flow (PEFR) were measured before and at the end of the study. The symptoms of asthma, the dosage of oral prednisolone and the number of hospitalizations due to asthma attack were recorded.